HEPCLUDEX 2 mg powder for solution for injection

DRUG4 trials

Sponsors

Gilead Sciences Inc., Karolinska University Hospital, Vir Biotechnology Inc.

Conditions

Chronic Hepatitis D InfectionChronic Hepatitis D Virus (HDV) Infectionhepatitis D

Phase 2

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy versus Bulevirtide in Participants with Chronic HDV Infection (ECLIPSE 3)

Active, not recruitingCTIS2024-520062-54-00

Vir Biotechnology Inc.Chronic Hepatitis D Virus (HDV) Infection

Start: 2025-07-23Target: 42Updated: 2026-01-07

Phase 3

Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D

RecruitingCTIS2023-504414-29-00

Karolinska University Hospitalhepatitis D

Start: 2023-06-19Target: 400Updated: 2023-05-12

A Phase 3 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide (ECLIPSE 2)

RecruitingCTIS2024-519282-22-00

Vir Biotechnology Inc.Chronic Hepatitis D Virus (HDV) Infection

Start: 2025-07-09Target: 136Updated: 2026-01-14

Phase 4

A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection

Active, not recruitingCTIS2022-501901-10-00

Gilead Sciences Inc.Chronic Hepatitis D Infection

Start: 2023-02-06Target: 220Updated: 2026-01-13